



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute PTO/SB/08A (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/611,363
		Filing Date	July 1, 2003
		First Named Inventor	DESJARLAIS, John R.
		Art Unit	1647
Examiner Name	TBA <i>R.M. DeBerry</i>		
Attorney Docket Number	Docket A-71486-2 (463077-240)		
Sheet	1	of	1

Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>JD</i>	A1 ††	US-2002/061525 A1	05-23-2002	Rodriguez et al. <i>Gelin et al.</i>	
<i>JD</i>	A2 †	US-6242213 B1	06-05-2001	Anderson	

OB
2na

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
<i>JD</i>	B1 †††	WO 00/15807 A *	03-23-2000	M & E Biotech		
	B2 ††	WO 00/67034 A	11-09-2000	Immunex Corporation		
	B3 †††	WO 01/25277 A	04-12-2001	Maxygen APS		
	B4 †††	WO 01/42298 A	04-21-2001	Kombluth		
	B5 †††	WO 01/64889 A	09-07-2001	Xencor		
	B6 ††	WO 02/18445 A	03-07-2002	Biogen, Inc.		
	B7 ††	WO 02/36141 A	05-10-2002	Immunex Corporation		
	B8 ††	WO 03/006154 A	01-23-2003	Xencor, Inc.		
	B9 ††	WO 03/029420 A	04-10-2003	Genentech, Inc.		
	B10 ††	WO 03/059281 A	07-24-2003	Xencor		
	B11 ††	WO 2004/081043 A	09-23-2004	Xencor		
	B12 ††	WO 2004/089982 A	10-21-2001	Xencor		
<i>JD</i>	B13 ††	WO 2005/035570 A	04-21-2005	Xencor, Inc.		
	B14 ††	WO 99/12965 A	03-18-1999	Biogen, Inc.		

NON PATENT LITERATURE DOCUMENTS					T ⁵
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>JD</i>	C1 †††	Lacey D. L. et al. "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation" Cell Cell Press, Cambridge, MA, US, vol. 93, April 17, 1998, pps. 165-176 *			
	C2 †††	Steed, P.M. et al. "Inactivation of TNF signaling by rationally designed dominant-negative TNF variants" Science (American Assoc for the Advancement of Science) vol. 301, no. 5641, (2003) pps. 1895-1898			
<i>JD</i>	C3 †††	Yasuda H. Et. Al. "Osteoclast Differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis -inhibitory factor and is identical to TRANCE/RANKL" Proc. Of Natl. Acad of Sci., (1998) vol. 95, pps. 3597-3602 *			

4818-1235-251316/26/2006/0:32 AM

Examiner Signature	<i>R.M. DeBerry</i>	Date Considered	9/5/06
--------------------	---------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2